MA40371A - Sélectivité efficace des protéines recombinées - Google Patents

Sélectivité efficace des protéines recombinées

Info

Publication number
MA40371A
MA40371A MA040371A MA40371A MA40371A MA 40371 A MA40371 A MA 40371A MA 040371 A MA040371 A MA 040371A MA 40371 A MA40371 A MA 40371A MA 40371 A MA40371 A MA 40371A
Authority
MA
Morocco
Prior art keywords
methods
expression
proteins
mammalian
recombinated
Prior art date
Application number
MA040371A
Other languages
English (en)
Other versions
MA40371B1 (fr
Inventor
Darya Burakov
Gang Chen
Dipali Deshpande
James Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA40371A publication Critical patent/MA40371A/fr
Publication of MA40371B1 publication Critical patent/MA40371B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Cette invention concerne un nouveau système d'expression comprenant un marqueur de mammifère sélectionnable qui favorise les modifications post-traductionnelles souhaitables des glycoprotéines. En particulier, l'invention concerne des procédés et des compositions permettant une expression optimale des protéines recombinées dans des cellules de mammifères par utilisation d'un système de marqueur de sélection basé sur des gènes gpt d'origine mammifère. L'invention concerne également des procédés qui facilitent la sélectivité, des copies d'expression améliorées ainsi qu'un rendement protéique des protéines recombinées amélioré dans des cellules de mammifères, ainsi que des procédés d'utilisation des systèmes d'expression gpt.
MA40371A 2014-08-19 2015-08-19 Sélectivité efficace des protéines recombinées MA40371B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462039416P 2014-08-19 2014-08-19
PCT/US2015/045793 WO2016028838A1 (fr) 2014-08-19 2015-08-19 Sélectivité efficace des protéines recombinées

Publications (2)

Publication Number Publication Date
MA40371A true MA40371A (fr) 2017-06-28
MA40371B1 MA40371B1 (fr) 2021-03-31

Family

ID=55347784

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40371A MA40371B1 (fr) 2014-08-19 2015-08-19 Sélectivité efficace des protéines recombinées

Country Status (27)

Country Link
US (4) US9732357B2 (fr)
EP (2) EP3183359B1 (fr)
JP (3) JP7115851B2 (fr)
KR (2) KR102406976B1 (fr)
CN (2) CN113293139A (fr)
AR (1) AR102333A1 (fr)
AU (3) AU2015305565B9 (fr)
BR (1) BR112017003074A2 (fr)
CA (1) CA2957036A1 (fr)
CY (1) CY1124079T1 (fr)
DK (1) DK3183359T3 (fr)
EA (1) EA035340B1 (fr)
ES (1) ES2849728T3 (fr)
HR (1) HRP20210301T1 (fr)
HU (1) HUE054069T2 (fr)
IL (3) IL287020B (fr)
LT (1) LT3183359T (fr)
MA (1) MA40371B1 (fr)
MX (2) MX2017002203A (fr)
MY (1) MY191745A (fr)
PL (1) PL3183359T3 (fr)
PT (1) PT3183359T (fr)
RS (1) RS61371B1 (fr)
SG (2) SG11201701121UA (fr)
SI (1) SI3183359T1 (fr)
TW (3) TWI777374B (fr)
WO (1) WO2016028838A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102333A1 (es) * 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
EP3749754A4 (fr) * 2018-02-08 2021-10-20 Applied Stemcell, Inc. Procédés de criblage de variant de gène cible
EP4049989A4 (fr) 2019-10-23 2023-11-29 Canon Kabushiki Kaisha Procédé de production d'un article en céramique, et article en céramique

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1392859B1 (fr) 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolement de cellules exprimant des proteines secretees
US7192737B2 (en) 2002-03-29 2007-03-20 Xoma Technology Ltd. Methods and materials for increasing expression of recombinant polypeptides
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
JP2005027599A (ja) * 2003-07-09 2005-02-03 Nara Institute Of Science & Technology 植物由来遺伝子を用いた遺伝子導入植物の選抜法
EP1586585A1 (fr) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Système d'expression pour la production des protéines de fusion IL-15/Fc et leur utilisation
HUE026199T2 (en) 2006-12-07 2016-05-30 Dow Agrosciences Llc New selectable marker genes
ES2522615T3 (es) 2007-06-04 2014-11-17 Regeneron Pharmaceuticals, Inc. Regiones de expresión y estabilidad potenciadas
KR100927803B1 (ko) * 2007-11-23 2009-11-23 한국생명공학연구원 식물 형질전환체를 선별하기 위한 마커로서 ｇｐｔ 유전자
ES2660036T3 (es) * 2007-12-07 2018-03-20 Zymogenetics, Inc. Moléculas de anticuerpo humanizadas específicas para IL-31
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
EP3037529B1 (fr) * 2008-12-09 2019-03-27 Halozyme, Inc. Polypeptides ph20 solubles étendus et leurs utilisations
EP2674495A1 (fr) 2012-06-14 2013-12-18 Sanofi Système d'expression dans CHO
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas

Also Published As

Publication number Publication date
JP2017525368A (ja) 2017-09-07
SI3183359T1 (sl) 2021-03-31
LT3183359T (lt) 2021-02-25
TW201615833A (zh) 2016-05-01
TW202124716A (zh) 2021-07-01
JP2020174681A (ja) 2020-10-29
BR112017003074A2 (pt) 2018-03-06
AU2023200752A1 (en) 2023-03-09
WO2016028838A1 (fr) 2016-02-25
CN107075549A (zh) 2017-08-18
AU2015305565A1 (en) 2017-03-09
KR102556383B1 (ko) 2023-07-17
AU2015305565B2 (en) 2020-04-30
IL295361A (en) 2022-10-01
EA201790241A1 (ru) 2017-06-30
IL287020B (en) 2022-09-01
IL250531A0 (en) 2017-03-30
EA035340B1 (ru) 2020-05-29
DK3183359T3 (da) 2021-02-01
AU2015305565B9 (en) 2020-05-21
KR20170055481A (ko) 2017-05-19
RS61371B1 (sr) 2021-02-26
EP3183359B1 (fr) 2020-12-16
CN107075549B (zh) 2021-04-20
EP3183359A4 (fr) 2018-04-04
JP7260510B2 (ja) 2023-04-18
US20210340564A1 (en) 2021-11-04
US11085053B2 (en) 2021-08-10
US9732357B2 (en) 2017-08-15
HUE054069T2 (hu) 2021-08-30
AU2020205336B2 (en) 2022-11-10
TWI832364B (zh) 2024-02-11
US20160053280A1 (en) 2016-02-25
US20200063159A1 (en) 2020-02-27
KR102406976B1 (ko) 2022-06-10
AU2023200752B2 (en) 2024-02-29
TW202246506A (zh) 2022-12-01
EP3183359A1 (fr) 2017-06-28
MA40371B1 (fr) 2021-03-31
JP7115851B2 (ja) 2022-08-09
PT3183359T (pt) 2021-02-03
IL287020A (en) 2021-12-01
AU2020205336A1 (en) 2020-08-06
CN113293139A (zh) 2021-08-24
EP3901274A1 (fr) 2021-10-27
SG11201701121UA (en) 2017-03-30
CY1124079T1 (el) 2022-05-27
SG10201707859RA (en) 2017-10-30
US20170335341A1 (en) 2017-11-23
MY191745A (en) 2022-07-13
HRP20210301T1 (hr) 2021-04-02
IL295361B2 (en) 2023-08-01
ES2849728T3 (es) 2021-08-20
PL3183359T3 (pl) 2021-08-02
IL295361B1 (en) 2023-04-01
AR102333A1 (es) 2017-02-22
IL250531B (en) 2021-10-31
JP2023076667A (ja) 2023-06-01
TWI719945B (zh) 2021-03-01
US10457959B2 (en) 2019-10-29
MX2017002203A (es) 2017-05-22
TWI777374B (zh) 2022-09-11
KR20220080215A (ko) 2022-06-14
MX2021009154A (es) 2021-09-10
CA2957036A1 (fr) 2016-02-25

Similar Documents

Publication Publication Date Title
MA40309A1 (fr) Anticorps anti-cd73 et leurs utilisations
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
MX2018005389A (es) Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
WO2016130704A3 (fr) Procédés et compositions pour analyser des composants cellulaires
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
AU2016259730A8 (en) Claudin-18.2-specific immunoreceptors and T cell epitopes
EA202192126A3 (ru) Способы сбора культур клеток млекопитающих
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
CA3011049A1 (fr) Compositions pour lier des domaines de liaison a l'adn et des domaines de clivage
EA201892137A1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
EP4219729A3 (fr) Compositions et procédés pour le ciblage efficace de transgènes
EP3543335A3 (fr) Protéines de fusion d'intéine solubles et procédés de purification de biomolécules
CR20180445A (es) Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
MA50280A (fr) Procédés et compositions pour améliorer l'immunogénicité de tumeurs [
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
MX2022012042A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2018003445A (es) Expresion de proteinas que contienen fc.